Single-dose @entity2380 versus XXXX in @entity14937 .

@entity1 @entity3071 @entity2380 @entity14937 @entity2059
BACKGROUND: The new antifungal triazoles @entity2059 and @entity2380 have revolutionized the treatment of @entity14937 . Both drugs have shown promising results in different dose schedules. OBJECTIVE: To compare the efficacy and safety of single oral dose treatment with @entity2380 versus @entity2059 in @entity1 with @entity14937 . METHODS: A total of 40 @entity1 with @entity14937 were allocated randomly to group A and group B. A single dose of @entity2380 (400 mg) or @entity2059 (400 mg) was given orally to group A or group B @entity1 , respectively. @entity1 were assessed mycologically by @entity3071 and culture. Culture was done from lesional and perilesional skin to quantify growth and to observe the effect of these drugs and the persistence/reappearance of the fungus in relation to relapse at 2 and 8 weeks. Relapse was defined as reappearance or worsening of clinical signs and symptoms or positive @entity3071 /culture after initial improvement. RESULTS: Thirteen (65%) @entity1 in the @entity2380 group and 4 (20%) @entity1 in the @entity2059 group became culture negative at the end of 8 weeks. Relapse was found to be higher in the @entity2059 group compared to the @entity2380 group (60 vs. 35%). A direct correlation was found between the relapse rate and positivity of perilesional skin for Malassezia furfur. CONCLUSION: In the same dosing, @entity2380 was found to be more effective than @entity2059 ; however, both drugs were found to be safe.
